Covid-19 causing significant delays to shipping times (Read More)
MyHep All (Sofosbuvir/Velpatasvir)
What is MyHep All (Sofosbuvir/Velpatasvir) used for?
MyHep All (Sofosbuvir/Velpatasvir) is combination of two antiviral substances used in the treatment of hepatitis C.
Sofosbuvir is a pangenotypic inhibitor of the RNA-dependent RNA polymerase NS5B of the hepatitis C virus (HCV) required for viral replication.
Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form a pharmacologically active uridine triphosphate analogue (GS-461203). Using NS5B polymerase, GS-461203 can be inserted into the HCV RNA chain under construction and act as a chain terminator. This active metabolite of sofosbuvir (GS-461203) suppressed the polymerase activity of HCV genotypes 1b, 2a, 3a, and 4a at concentrations that caused 50% inhibition (IC50) of virus in the range from 0.7 to 2.6 ?mol.
The active metabolite of sofosbuvir (GS-461203) does not inhibit human DNA and RNA polymerase and human mitochondrial RNA polymerase.
Velpatasvir also has antiviral activity against the hepatitis C virus. It affects the NS5A protein, and thus helps reduce viral load.
How should I use MyHep All (Sofosbuvir/Velpatasvir)?
Always follow your doctor`s instructions when using MyHep All (Sofosbuvir/Velpatasvir) to get the safest and most effective results from treatment.
As a rule, the dosage is 1 tablet once a day.
Duration of treatment is 12 weeks.
What are the side effects of MyHep All (Sofosbuvir/Velpatasvir)?
The use of MyHep All (Sofosbuvir/Velpatasvir) may cause side effects in some patients, such as headache, fatigue, nausea.
However, it should be noted that similar and other side effects occurred with such frequency when used in the placebo group.
There is insufficient data (less than 300 outcomes of pregnancies) on the use of MyHep All (Sofosbuvir/Velpatasvir) during pregnancy. MyHep All (Sofosbuvir/Velpatasvir) should be avoided during pregnancy.
The results of preclinical studies did not reveal the direct or mediated reproductive toxicity of sofosbuvir.
It is not known whether MyHep All (Sofosbuvir/Velpatasvir) and its metabolites penetrate into human breast milk, although the excretion of metabolites in breast milk has been established in preclinical studies.
Since the risk to the newborn cannot be ruled out, MyHep All (Sofosbuvir/Velpatasvir) should not be used during breastfeeding.